Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T Abstract from Mayo Clinic (Vile group) using pela
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(319)
•••
Comment by jimsenioron Jun 02, 2023 11:21am
147 Views
Post# 35476950

RE:RE:RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pelaHello Henry,

Let me introduce you to James P. Allison, 2018 Nobel Prize Winner for Physiology or Medicine. The first for cancer in 28 years.

He is best known for elucidating the mechanism behind T Cells activation, and pioneering the first immune checkpoint inhibitor. Yervoy.

I cannot remember his exact words, but he asserted that animal models were essential to his work.

I believe Allison would be very interested indeed in the upcoming  mBC and CAR T abstracts.

To digress, neither am I happy with the share price.  Alas, ATM financed companies are vulnerable.

The company is gathering very compelling data.

We shall have to hold for a while longer.

Best of luck.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities